

SPECTRUM PHARMACEUTICALS INC

Form 10-K/A

May 01, 2006

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K/A
Amendment No. 1**

**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**
For the fiscal year ended December 31, 2005

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**
For the transition period from **to**
Commission File Number: 000-28782
Spectrum Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
*(State or other jurisdiction of
incorporation or organization)*

93-0979187
*(I.R.S. Employer
Identification No.)*

157 Technology Drive
Irvine, California
(Address of principal executive offices)

92618
(Zip Code)

Registrant's telephone number, including area code:
(949) 788-6700

Securities registered pursuant to Section 12(b) of the Act:
None

Securities registered pursuant to Section 12(g) of the Act:
Common Stock, \$.001 par value
Common Stock Purchase Warrants

Rights to Purchase Series B Junior Participating Preferred Stock

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the
Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained
herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K

Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, or a non-accelerated filer
(as defined in Rule 12b-2 of the Act).

Large accelerated filer

Accelerated filer

Non-accelerated filer

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12B-2 of the Exchange Act).

Yes No

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2005 was \$64,185,904 based on the closing sale price of such common equity on such date.

As of April 27, 2006 there were 24,320,802 shares of the registrant's common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

There are no documents incorporated by reference herein.

EXPLANATORY NOTE

The primary purpose of this Amendment is to provide information required by Items 10, 11, 12, 13 and 14 of Part III of this report on Form 10-K, which the registrant intended to incorporate by reference from the registrant's proxy statement for the 2006 Annual Meeting of Stockholders. Items 10, 11, 12, 13 and 14 to the Annual Report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission on March 15, 2006, are hereby amended and restated in their entirety as follows.

TABLE OF CONTENTS

| | Page |
|--|-------------|
| <u>PART III</u> | |
| <u>Item 10. Directors and Executive Officers of the Registrant</u> | 2 |
| <u>Item 11. Executive Compensation</u> | 7 |
| <u>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u> | 10 |
| <u>Item 13. Certain Relationships and Related Transactions</u> | 14 |
| <u>Item 14. Principal Accountant Fees and Services</u> | 14 |
| <u>Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K</u> | 15 |
| <u>Signatures</u> | 16 |
| <u>EXHIBIT 2.1</u> | |
| <u>EXHIBIT 10.1</u> | |
| <u>EXHIBIT 10.2</u> | |
| <u>EXHIBIT 10.3</u> | |
| <u>EXHIBIT 31.1</u> | |
| <u>EXHIBIT 31.2</u> | |

Table of Contents

PART III

Item 10. Directors and Executive Officers of the Registrant

Directors

Our Board of Directors consists of six annually elected directors. The Nominating and Corporate Governance Committee has nominated Richard D. Fulmer, Stuart M. Krassner, Anthony E. Maida, Dilip J. Mehta, Rajesh C. Shrotriya and Julius A. Vida for election to the Board at the upcoming annual meeting.

On September 20, 2005, Mr. Fulmer, was elected to the Board to fill the vacancy created by the Board's increase in the number of directors from five to six. Under Delaware law, a director elected by the Board of Directors to fill a vacancy serves until the next annual meeting of stockholders and until his successor is elected and qualified.

The following provides information regarding our nominees to the Board of Directors, their ages, the year in which each first became a director of the Company, their principal occupations or employment during the past five years and any family relationship with any other director or executive officer of the Company:

***Richard D. Fulmer,
M.B.A.***

Mr. Fulmer, 60, has been a director of Spectrum since September 2005. His career spans over thirty years, including twenty-four years spent at Pfizer, Inc., where he held senior positions in marketing, business development, and general management. Mr. Fulmer retired from Pfizer in 2001 and since that time has served as a self-employed consultant and advisor to healthcare companies. He is an Advisory Board Member of Avaan Therapeutics, Inc. From 1998 until his retirement, Mr. Fulmer was Vice President and General Manager of Pfizer's US Veterinary healthcare business, with accountability for the management of sales, marketing, and medical operations. Prior to that assignment, Mr. Fulmer served as Pfizer's Vice President for Licensing and Development from 1993 to 1997, with responsibility for corporate licensing and business development activity, which included the acquisition of new drugs and technology for the global pharmaceutical business. Chief among his accomplishments was the formation of a strategic alliance with Eisai for the Alzheimer's drug Aricept. He also led the effort to license the cholesterol reduction product Lipitor, and was also responsible for creating a multi-company alliance for the commercialization of Exubera, a pulmonary insulin product. During his tenure in licensing, he became a prominent speaker at industry conferences and a member of the Licensing Executive Society. Mr. Fulmer was also a Vice President of Marketing for Pfizer where he played a key role in the introduction and commercial success of several market leading drugs, including Diflucan, Zoloft, and Glucotrol. Prior to joining Pfizer, Mr. Fulmer was a Senior Financial Analyst for the Ford Motor Company and served as a Captain in the United States Marine Corps. He received a MBA in Finance from George Washington University in 1973. He also holds a B.S. in Economics from the University in Oregon (1967) and a Diploma in International Business from the Netherlands School of Business, Nijenrode University.

Table of Contents***Stuart M. Krassner,
Sc.D., Psy.D***

Dr. Krassner, 70, has been a director of Spectrum Pharmaceuticals, Inc. since December 2004 and was previously a member of our Scientific Advisory Board from 1996 to 2001. Dr. Krassner's career spans four decades of experience in various positions at the University of California, Irvine (UCI), most recently as Professor Emeritus of Developmental and Cell Biology at the School of Biological Sciences. While at UCI, he developed and reinforced FDA and NIH compliance procedures for UCI-sponsored human clinical trials, established UCI's first Institutional Review Board, and at one time headed all contract and grant activities. Dr. Krassner has also been retained by a number of public and private pharmaceutical, medical device and other companies to provide scientific and regulatory advisory services, including FDA compliance. Dr. Krassner's work has been published in numerous peer-reviewed U.S. journals. Dr. Krassner has been awarded grants from the National Institute of Health, the National Science Foundation and the World Health Organization. Dr. Krassner has been a member of the American Society of Protozoology, the American Society of Tropical Medicine and Hygiene, the Corporation of the Marine Biological Laboratories, Woods Hole, MA, and Sigma Xi, among others. Dr. Krassner received his Sc.D. from the Bloomberg School of Public Health at Johns Hopkins University. He holds a B.S. in Biology from Brooklyn College.

***Anthony E. Maida, III,
MA, MBA***

Mr. Maida, 54, has been a director of Spectrum since December 2003. Mr. Maida has been the Acting Chairman of Dendri Therapeutics, Inc., a startup company focused on the clinical development of therapeutic vaccines for patients with cancer, since 2003. Additionally, Mr. Maida has been serving as Chairman, Founder and Director of BioConsul Drug Development Corporation since 1999, providing consulting services to large and small biopharmaceutical firms in the clinical development of oncology products and product acquisitions and to venture capital firms evaluating life science investment opportunities. Mr. Maida served as the President and Chief Executive Officer of Replicon NeuroTherapeutics, Inc., a biopharmaceutical company focused on the therapy of patients with tumors (both primary and metastatic) of the central nervous system (CNS) where he successfully raised financing from both venture capital and strategic investors and was responsible for all financial and operational aspects of the company, from June 2001 to July 2003. From 1999 to 2001, Mr. Maida held positions as Interim Chief Executive Officer for Trellis Bioscience, Inc., a private biotechnology company that addresses high clinical stage failure rates in pharmaceutical development, and CancerVax Corporation, a biotechnology company dedicated to the treatment of cancer. From 1992 until 1999, Mr. Maida served as President and CEO of Jenner Biotherapies, Inc., a biopharmaceutical company. From 1980 to 1992, Mr. Maida served in senior management positions with various companies including President and Chief Executive Officer of Cell Path, Inc., a biosciences company specializing in drug discovery and development, and Vice President Finance and Chief Financial Officer of Data Plan, Inc., a wholly owned subsidiary of Lockheed Corporation. Additionally, Mr. Maida currently works in the laboratory of Kit S. Lam, M.D., Ph.D., University of California, Medical Center, Department of Hematology and Oncology, where he is completing his doctoral work in immunology (advanced to Doctoral Candidacy). Mr. Maida serves on the Advisory Boards of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia) and Innovera Life Science Fund and serves as a consultant and technical analyst for North Sound Capital, one of our large stockholders, and vFinance, both financial services companies. Additionally, Mr. Maida has been retained by Takeda

Chemical Industries, Ltd. (Osaka, Japan) and Novel Bioventures to conduct corporate and technical due

Table of Contents

diligence on investment opportunities. Mr. Maida is a speaker at industry conferences and is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, the Society of Neuro-Oncology, the International Society for Biological Therapy of Cancer, the American Association of Immunologists and the Society of Toxicology. Mr. Maida received a B.A. Degree in History from University of Santa Clara 1975, received a B.A. degree in Biology from San Jose State University 1977, a MBA from the University of Santa Clara 1978, and received a MA in toxicology from San Jose University 1986.

***Dilip J. Mehta, M.D.,
Ph.D***

Dr. Mehta, 73, has been a director of Spectrum since June 2003 and member of our Scientific Advisory Board since 2001. Dr. Mehta has been self-employed as a pharmaceutical consultant since 1998. Dr. Mehta is a venture partner at Radius Ventures, LLC in New York. Dr. Mehta is a current member of the Psychopharmacology Advisory Committee to the U.S. Food and Drug Administration. From 1982 until he retired in 1997, Dr. Mehta held a number of executive management positions with Pfizer Inc., a pharmaceutical company, including Senior Vice President, U.S. Clinical Research, with responsibility for clinical research (Phases 1, 2 and 3) including data processing and statistical analysis for Pfizer Inc.'s drugs in the U.S., as well as supervised submissions of NDAs for Cardura, Norvasc, Zoloft, Zithromax, Diflucan, Unasyn, Trovan, Viagra, Geodon, and a number of other drugs/supplements. Dr. Mehta serves as a member of the Board of Directors of Esvee Pharmaceuticals, Pvt. Ltd. (Pune, India), and Bharat Serums & Vaccines Limited (Mumbai, India). From 1993 until 1997, Dr. Mehta served as Chair, Efficacy Section for the Pharmaceutical Research and Manufacturers of America (PhRMA) in the International Conference on Harmonization and was a PhRMA topic leader for one of the Expert Working Group in Efficacy. From 1966 until 1982, Dr. Mehta held the position of Group Director, Clinical Research in the U.S. for Hoechst AG with supervision of Internal Medicine, Metabolic and Infectious Diseases and Cardiovascular groups. Dr. Mehta graduated from the University of Bombay, India, and holds an M.D., and received a Ph.D. in Pharmacology. Dr. Mehta was a Research Fellow in Clinical Pharmacology at Cornell University Medical College.

***Rajesh C. Shrotriya,
M.D***

Dr. Shrotriya, 62, has been Chairman of the Board, Chief Executive Officer and President since August 2002 and a director of Spectrum since June 2001. From September 2000 to August 2002, Dr. Shrotriya served as President and Chief Operating Officer of Spectrum. Dr. Shrotriya also serves as a member of the Board of Directors of Antares Pharma, Inc., a drug delivery systems company. Prior to joining Spectrum Pharmaceuticals, Inc., Dr. Shrotriya held the position of Executive Vice President and Chief Scientific Officer from November 1996 until August 2000, and as Senior Vice President and Special Assistant to the President from November 1996 until May 1997, for SuperGen, Inc., a publicly-held pharmaceutical company focused on drugs for life-threatening diseases, particularly cancer. From August 1994 to October 1996, Dr. Shrotriya held the positions of Vice President, Medical Affairs and Vice President, Chief Medical Officer of MGI Pharma, Inc., an oncology-focused biopharmaceutical company. Dr. Shrotriya spent 18 years at Bristol-Myers Squibb Company in a variety of positions most recently as Executive Director, Worldwide CNS Clinical Research. Previously, Dr. Shrotriya held various positions at Hoechst Pharmaceuticals, most recently as Medical Advisor. Dr. Shrotriya was an attending physician and held a

courtesy appointment at St. Joseph Hospital in Stamford, Connecticut. In addition, he received a certificate for Advanced Biomedical Research

Table of Contents

Management from Harvard University. Dr. Shrotriya received his M.D. degree from Grant Medical College, Bombay, India, in 1974; his D.T.C.D. (Post Graduate Diploma in Chest Diseases) degree from Delhi University, V.P. Chest Institute, Delhi, India, in 1971; M.B.B.S. (Bachelor of Medicine and Bachelor of Surgery equivalent to an M.D. degree in the U.S.) from the Armed Forces Medical College, Poona, India, in 1967; and a B.S. with Chemistry degree from Agra University, Aligarh, India, in 1962.

Julius A. Vida, Ph.D.

Dr. Vida, 77, has been a director of Spectrum since April 2003. Dr. Vida serves as a member of the Board of Directors of Medarex, Inc., a NASDAQ listed company focused on the discovery and development of human antibody-based therapeutic products, CSS Albachem Ltd., (UK), a biotechnology company which produces chemically synthesized custom peptides and proteins, FibroGen, Inc., a pharmaceutical company, Osteo Screen, Inc., a pharmaceutical company which attempts to find new drugs to slow bone loss, and YM Biosciences, Inc. (Canada), a pharmaceutical development company that focuses on cancer therapeutics. Since 1993, Dr. Vida has been a self-employed pharmaceutical consultant with VIDA International Pharmaceutical Consultants. From 1975 until his retirement in 1993, Dr. Vida held various positions at Bristol-Myers Squibb and its predecessors. From 1991 to 1993, Dr. Vida was Vice President, Business Development, Licensing and Strategic Planning, and from 1985 to 1991, he was Vice President, Licensing. Dr. Vida graduated from Pazmany Peter University, Budapest, Hungary, holds an M.S. and a Ph.D. in Organic Chemistry from Carnegie Institute of Technology, was a Postdoctoral Fellow at Harvard University, and holds an M.B.A. from Columbia University.

Executive Officers

The following provides information regarding our Executive Officers, their ages, the year in which each first became an officer of the Company and descriptions of their backgrounds.

Name and Age

Rajesh C. Shrotriya,
M.D. (62)
Chairman of the Board,
Chief
Executive Officer and
President

Information regarding Dr. Shrotriya is provided above.

Luigi Lenaz, M.D. (65)
Chief Scientific Officer

Dr. Lenaz, has served as Chief Scientific Officer since February 2005. From November 2000 until February 2005, Dr. Lenaz served as the President of Spectrum's Oncology Division. Prior to joining Spectrum Pharmaceuticals, Inc., he was Senior Vice President of Clinical Research and Medical Affairs from October 1997 to June 2000 of SuperGen, Inc., a NASDAQ listed pharmaceutical company dedicated to battling cancer. Previously, he was Senior Medical Director, Oncology Franchise Management for Bristol-Myers Squibb, a NYSE listed pharmaceutical company, from 1990 to 1997 and was Director, Scientific Affairs, Anti-Cancer for Bristol-Myers Squibb from 1978 to 1990. Dr. Lenaz was a Post Doctoral Fellow at both the Memorial Sloan-Kettering Cancer Center in New York and the National Cancer Institute in Milan, Italy. He received his medical training at the University of Bologna Medical School in Bologna, Italy.

Shyam Kumaria (56)
Vice President Finance

Mr. Kumaria, has served as Vice President Finance since December 2003. From 1996 to 2003, he provided financial and management consulting services to private companies. From 1984 to 1996, he served in senior executive and management positions for several companies including Deloitte & Touche. Mr. Kumaria became a Chartered Accountant in London, England in 1973 and a Certified Public Accountant in 1978. He received an Executive MBA from Columbia University in 1984.

Table of Contents

Audit Committee

The Audit Committee is currently comprised of Messrs. Maida (Chair) and Fulmer, and Drs. Krassner and Mehta, each of whom satisfies the NASDAQ and SEC rules for Audit Committee membership. The Audit Committee held 7 meetings during 2005. It acts pursuant to a written charter which is posted on the Company's website at www.spectrumpharm.com. The Board of Directors has determined that Mr. Maida is an Audit Committee financial expert within the meaning of the SEC rules and satisfies the financial sophistication requirements of the NASDAQ Listing Standards. Principal responsibilities of the Audit Committee include but are not limited to:

Appointing, compensating, retaining and overseeing the work of the independent auditor;

Reviewing independence qualifications and quality controls of the independent auditor;

Oversee and monitor internal controls, procedures, the audit function, accounting procedures and financial reporting process; and

Reading and discussing with management and the independent auditor the annual audited, and quarterly unaudited, financial statements.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our executive officers and directors, and persons who beneficially own more than ten percent of our Common Stock, to file initial reports of ownership and reports of changes in ownership with the SEC and the National Association of Securities Dealers, Inc. Executive officers, directors and persons who beneficially own more than ten percent of our Common Stock are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.

Based solely upon our review of the copies of reporting forms furnished to us, and written representations that no other reports were required, we believe that all filing requirements under Section 16(a) of the Exchange Act applicable to our directors, officers and any persons holding 10% or more of our Common Stock with respect to our fiscal year ended December 31, 2005, were satisfied on a timely basis, except as follows: Mr. Fulmer failed to file an initial report on Form 3 due within 10 days of being appointed as a director of our Board of Directors on September 20, 2005. Mr. Fulmer filed a Form 3 on December 7, 2005.

Code of Business Conduct and Ethics

We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including the principal executive officer, principal financial officer, principal accounting officer, controller or persons performing similar functions as required by the Sarbanes-Oxley Act of 2002. A copy of the Code of Business Conduct and Ethics will be provided to any person, without charge, upon oral request to (949) 788-6700 or upon written request to Investor Relations, Spectrum Pharmaceuticals, Inc., 157 Technology Drive, Irvine, CA 92618. Waivers from, and amendments to, if any, the Code of Business Conduct and Ethics that apply to our principal executive officer, principal financial officer, principal accounting officer, controller or persons performing similar functions, if any, will be posted on our website at www.spectrumpharm.com.

Table of Contents**Item 11. Executive Compensation****Executive Compensation Summary Table**

The following table sets forth information concerning total compensation during each of the past three fiscal years for services rendered to the Company earned or paid to the Chief Executive Officer, and the two executive officers whose annual salary and bonus exceeded \$100,000 in fiscal year 2005 (the Named Executive Officers).

| Name and Principal Position | Year | Annual Compensation | | Long Term Compensation Awards | | All Other Compensation (2) |
|--|------|---------------------|------------|-------------------------------|-----------------------------------|----------------------------|
| | | Salary | Bonus | Restricted Stock Awards (1) | Securities Underlying Options (#) | |
| Rajesh Shrotriya (3)(4) Chairman, Chief Executive Officer and President | 2005 | \$ 500,000 | \$ 250,000 | \$ 0 | 500,000 | \$ 9,774 |
| | 2004 | 500,000 | 250,000 | 0 | 450,000 | 1,374 |
| | 2003 | 318,000 | 500,000 | 0 | 440,000 | 1,374 |
| Luigi Lenaz (5) Chief Scientific Officer | 2005 | 310,000 | 60,000 | 127,800 | 200,000 | 3,041 |
| | 2004 | 280,500 | 60,000 | 0 | 150,000 | 1,374 |
| | 2003 | 232,000 | 50,000 | 0 | 140,000 | 1,374 |
| Shyam Kumaria (6)(7) Vice President, Finance | 2005 | 220,000 | 40,000 | 85,200 | 90,000 | 9,774 |
| | 2004 | 200,000 | 40,000 | 0 | 75,000 | 1,374 |
| | 2003 | 40,174 | | 0 | 50,000 | 0 |

(1) The holders of restricted stock are entitled to vote and receive dividends, if issued, on the shares of Common Stock covered by the restricted stock grant.

(2) Amounts include annual 401(k) matching contribution made by us in shares of our Common Stock and premiums paid on life insurance policies, benefits that are offered to all our employees.

- (3) On January 1, 2006, 80,000 restricted shares of our Common Stock were awarded to Dr. Shrotriya based on the Compensation Committee's review of corporate performance, individual achievements and as an inducement for future performance. These shares vest in installments of 25% annually beginning January 1, 2006.
- (4) On January 1, 2006, an option to purchase up to 200,000 shares of our Common Stock was awarded to Dr. Shrotriya based upon the Compensation Committee's review of corporate performance, individual achievements, and as an inducement for future performance. The option vests in installments of 25% annually beginning

January 1, 2006.

- (5) On December 6, 2005, 30,000 restricted shares of our Common Stock were awarded to Dr. Lenaz based on the Compensation Committee's review of corporate performance and individual achievements for the 2005 fiscal year, and as an inducement for future performance. These shares vest in installments of 25% annually beginning January 1, 2006.
- (6) On December 6, 2005, 20,000 restricted shares of our Common Stock were awarded to Mr. Kumaria based on the Compensation Committee's review of corporate performance and individual achievements for the 2005 fiscal year, and as an inducement for future performance.

These shares
vest in
installments of
25% annually
beginning
January 1, 2006.

- (7) Employment
commenced on
December 8,
2003. Prior to
that date,
Mr. Kumaria
worked as a
consultant to the
Company, for
which he was
paid \$27,225.

Table of Contents**Option Grants for Fiscal 2005**

The following table sets forth for the year ended December 31, 2005, the grants of our Common Stock options to the Named Executive Officers.

| Name | Options Granted (No. of Shares) | Individual Grants % of Total Options Granted to Employees in | | | Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for | |
|------------------|--|--|------------------------------|--------------------|--|-------------|
| | | Fiscal Year | Exercise Price (\$/Sh) | Expiration Date | Option Term(1) 5% 10% | |
| Rajesh Shrotriya | 500,000(2) | 35.3% | \$6.66 | 01/03/2015 | \$2,094,219 | \$5,307,162 |
| Luigi Lenaz | 100,000(2) | 7.1% | \$6.66 | 01/03/2015 | 418,844 | 1,061,432 |
| | 100,000(3) | 7.1% | \$4.26 | 12/06/2015 | 267,909 | 678,934 |
| Shyam Kumaria | 50,000(2) | 3.5% | \$6.66 | 01/03/2015 | 209,422 | 530,716 |
| | 40,000(3) | 2.8% | \$4.26 | 12/06/2015 | 107,164 | 271,574 |

(1) The assumed 5% and 10% annual rates of stock price appreciation are for illustrative purposes only. Actual stock prices will vary from time to time based upon market factors and the Company's financial performance. No assurance can be given that such rates will be achieved. Unless the market price of the Common Stock appreciates over the Option term, no value will be

realized from the Option grants made to the Named Executive Officers.

- (2) These options vest in equal increments of 25% annually from the date of grant and have a ten-year term.
- (3) These options vest in equal increments of 25% annually from January 1, 2006 and have a ten-year term.

Option Exercises and Values for Fiscal 2005

The following table sets forth information concerning our Common Stock option exercises during 2005 and year-end values as of December 31, 2005, for the Named Executive Officers.

| Name | No. of | Value | Number of Securities | | Value of Unexercised | |
|------------------|----------------------|----------|----------------------|------------------------|-------------------------------------|---------------|
| | Shares | | Options at Year End | Underlying Unexercised | In-the-Money Options at Year End(1) | Unexercisable |
| | Acquired on Exercise | Realized | Exercisable | Unexercisable | Exercisable | Unexercisable |
| Rajesh Shrotriya | 0 | \$0 | 967,600 | 604,000 | \$964,303 | \$0 |
| Luigi Lenaz | 0 | 0 | 359,150 | 225,000 | 494,704 | 0 |
| Shyam Kumaria | 0 | 0 | 92,500 | 122,500 | 0 | 0 |

- (1) Based upon the closing sale price of our Common Stock on December 30, 2005, as reported by the NASDAQ National Market, of \$4.23 per common share.

Table of Contents

Cash Compensation. Each non-employee director receives an annual retainer of \$20,000, \$2,000 for each in-person Board of Directors meeting attended, \$1,000 for each additional in-person Board of Director Meetings held on the day following an in-person Board Meeting and \$1,000 for each telephonic Board of Director s meeting attended. In addition, the lead director receives an annual retainer of \$1, the amount the lead director requested.

The Chairperson of our Audit Committee receives \$3,000 for each committee meeting attended (whether in-person or telephonically) while the other committee members of the Audit Committee receive \$1,000 for each committee meeting attended. The Chairperson of our Compensation Committee receives \$1,000 for each committee meeting attended (whether in-person or telephonically) while the other committee members of the Compensation Committee receive \$500 for each committee meeting attended. Each non-employee director serving as a member of our Placement Committee receives \$250 per committee meeting (whether in-person or telephonically) or action by Unanimous Written Consent. Each non-employee director serving a member of our Product Acquisition Committee receives \$2,000 per full day committee meeting and \$1,000 per half day committee meeting. Our directors are also reimbursed for certain expenses incurred in connection with attendance at Board meetings. Directors who are also employees of the Company receive no compensation for service as directors.

Stock Grants. On December 6, 2005, we granted to each non-employee director 5,000 restricted shares of our Common Stock. These shares vest in installments of 25% annually beginning January 1, 2006.

Stock Options. On January 3, 2005, we granted to each non-employee director an option to purchase up to 20,000 shares of our Common Stock at \$6.66 per share. These options vest in installments of 25% annually as of the date of grant and have maximum ten-year terms. On March 14, 2005, we granted each of Dr. and Mr. Kessler, directors at that time who did not stand for re-election to the Board at the annual stockholders meeting on June 10, 2005, an option to purchase up to 10,000 shares of our Common Stock at \$6.92 per share, which options vested in their entirety on June 10, 2005; and on April 12, 2005, the Compensation Committee accelerated the vesting of all previously granted options to Dr. and Mr. Kessler that had not yet vested. On September 20, 2005, we granted Mr. Fulmer an option to purchase up to 10,000 shares of our Common Stock at \$5.13 per share. This option vests in installments of 25% every three months beginning on the date of grant and has a maximum ten-year term. On December 6, 2005, we granted to each non-employee director an option to purchase up to 15,000 shares of our Common Stock at \$4.26 per share. These options vest in installments of 25% annually beginning January 1, 2006 and have maximum ten-year terms. The exercise price of all of the above options was the fair market value based upon the closing sale price of the Company s Common Stock on the date prior to the grant.

Employment Agreements and Severance Arrangement

We have entered into employment agreements with two of our Named Executive Officers, Dr. Shrotriya and Dr. Lenaz. The agreements require each executive to devote his full working time and effort to the business and affairs of the Company during the term of the agreement. The agreements provide for an annual base salary with annual increases, periodic bonuses and option grants as determined by the Compensation Committee of our Board of Directors.

Each officer s employment may be terminated by us with or without cause as defined in the agreement. The agreements provide for certain guaranteed severance payments and benefits if the officer s employment is terminated without cause, if the officer s employment is terminated due to a change in control or is adversely affected due to a change in control and the officer resigns or if the officer decides to terminate his employment due to a disposition of a significant amount of assets or business units. The guaranteed severance payment includes a payment equal to the officer s annual base salary and other cash compensation, and any approved bonus. The officer is also entitled to two years medical, dental and other benefits for two years following termination. In addition, all options held by the officer shall immediately vest and will be exercisable for one year from the date of termination; provided, however, if the Board determines that the officer s employment is being terminated for the reason that the shared expectations of the officer and the Board are not being met, in the Board s judgment, then the options currently held by the officer will vest in accordance with their terms for up to one year after the date of termination, with the right to exercise those options, when they vest, for approximately thirteen (13) months after the date of termination. The agreements also provide that, upon his retirement, all options held by the officer will become fully vested.

Table of Contents

Following termination of the officer's employment, the officer shall be permitted to continue in his usual occupation and shall not be prohibited from competing with us except during the two (2) year severance period and in the specific industry market segments in which we compete and which represent twenty percent (20%) or more of our revenues.

The following table sets forth information regarding the employment agreements for each Named Executive Officer, including each Named Executive Officer's current base salary and each agreement's ending date:

| Name | Current Base | |
|------------------|---------------------|-----------------------|
| | Salary | Ending Date(1) |
| Rajesh Shrotriya | \$ 500,000 | December 31, 2006 |
| Luigi Lenaz | \$ 310,000 | July 1, 2007 |

(1) The employment agreement automatically renews for a one-year term unless either party gives written notice at least 90 days prior to the commencement of the next year of such party's intent not to renew the agreement.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

The Compensation Committee is comprised of Drs. Krassner, Mehta and Vida. None of the members of the Board's Compensation Committee is or has been an officer or employee of the Company. None of the Company's executive officers has served as a director or Compensation Committee member of any other entity, any of whose executive officers served as a director or Compensation Committee member of our board of directors.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Equity Compensation Plan Information

The following table summarizes all equity compensation plans including those approved by security holders and those not approved by security holders, as of December 31, 2005.

| Number of Securities to be Issued Upon Exercise of Outstanding Options, | Weighted-average Exercise Price of | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans |
|--|---|---|
|--|---|---|

| Plan Category | Warrants or Rights | Outstanding Options, Warrants and Rights | (excluding securities reflected in column (a)) |
|---|---------------------------|---|---|
| Equity compensation plans approved by security holders (1) | 3,661,682 | \$ 6.98 | 3,251,228 |
| Equity compensation plans not approved by security holders(2) | 726,000 | \$ 6.45 | 0 |
| Employee Stock Purchase Plan approved by security holders | N/A | N/A | 9,444 |
| Total | 4,387,682 | \$ 6.90 | 3,260,672 |

(1) Common Stock.
We have three stock incentive plans: the 1991 Stock Incentive Plan (1991 Plan), the 1997 Stock Incentive Plan (1997 Plan) and the 2003 Amended and Restated Incentive Award Plan (2003 Plan), (collectively, the Plans). As of December 31, 2005, we are not granting any more options pursuant to the 1991 and 1997 Plans. The 2003 Plan authorizes the grant, in conjunction with all of our other Plans, of incentive awards, including stock options, for the purchase of up to a total of 30% of our issued and outstanding stock at the time of grant. Thus, the

authorized and available shares may fluctuate over time.

- (2) The number represents 726,000 shares of Common Stock issuable upon exercise of warrants issued to non-employees of the Company under equity compensation Plans approved by our Board of Directors that we believe are not required to be approved by our stockholders pursuant to the rules of the NASDAQ Stock Market. We issued these warrants in circumstances that enable us to adequately compensate, without the payment in cash, for outside consultant services, primarily placement agents who assist us in raising funds for our operations, in order to conserve our cash for operating activities. The number of securities remaining

available for
future issuance
under these types
of equity
compensation
plans is zero;
however, the
Board of
Directors may
approve
additional
issuance of
warrants under
circumstances
that it decides are
appropriate.
These warrants
are typically
exercisable for
five years and
have equitable
anti-dilution
rights for stock
splits, stock
dividends,
reclassifications,
compulsory
share exchanges,

Table of Contents

distributions of indebtedness, assets, rights, warrants or subscriptions, merger, consolidation, sale of assets, tender offer or other exchanges of the entire class of Common Stock.

The number does not include warrants issued to investors in connection with financing transactions. As of December 31, 2005, there were outstanding investor warrants to purchase up to an aggregate of 9,194,703 shares of our Common Stock, with a weighted average exercise price of \$7.26.

Further details regarding warrants issued by the Company are included in footnotes 8 and 9 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2005.

Security Ownership of Certain Beneficial Owners and Management

Based on information provided to us by the holders, the following table shows the amount of our Preferred Stock and Common Stock beneficially owned on April 27, 2006 (unless otherwise indicated) by holders of more than 5% of the outstanding shares of any class of our voting securities. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission (SEC) and generally includes voting and investment power with respect to securities, unless footnoted to the contrary.

| Name and Address of Beneficial Owner | Preferred Shares Beneficially Owned(1) | Percent of Preferred Stock Outstanding(2) | Common Shares and Common Equivalents Beneficially Owned(3) | Percent of Common Shares Outstanding(3) |
|---|---|--|---|--|
| David M. Knott(6)(7) c/o Dorset Management Corporation 485 Underhill Boulevard, Suite 205 Syosset, NY 11791 | 0 | 0.00% | 1,598,300 | 6.60% |
| North Sound Capital LLC(4)(5)(8)(9)(10)(11) 20 Horseneck Lane Greenwich, CT 06830 | 198 | 47.38% | 3,729,347 | 14.91% |
| Omicron Capital, L.P.(5)(9)(10)(12) 650 Fifth Avenue New York, NY 10019 | 150 | 35.90% | 506,314 | 2.09% |
| Samuel D. Isaly(6)(13) c/o OrbiMed Advisors LLC 767 Third Avenue, 30 th Floor New York, NY 10017 | 0 | 0.00% | 2,857,143 | 11.58% |
| SDS Capital Group SPC, Ltd.(4)(6)(8)(10)(14) c/o SDS Management, LLC 53 Forest Avenue, Suite 201 Old Greenwich, CT 06870 | 49 | 11.70% | 1,861,146 | 7.38% |

(1) The amount includes the combined number of shares of both our Series D Preferred Stock and our Series E Preferred Stock

owned by the entity as of April 27, 2006. There are no outstanding shares of any other series of our Preferred Stock.

- (2) Represents the percentage of the combined number of outstanding shares of both our Series D and Series E Preferred Stock.
- (3) Shares of Common Stock owned as of April 27, 2006 and shares of Common Stock subject to Preferred Stock, call options and warrants currently convertible or exercisable, or convertible or exercisable within 60 days of April 27, 2006, are deemed beneficially owned and outstanding for computing the percentage of the person holding such securities, but are not considered outstanding for computing the

percentage of
any other
person. Share
numbers and
percentages for
each
stockholder
include all

Table of Contents

such shares of common stock that may be acquired through the conversion or exercise of convertible preferred stock, warrants or options held by such stockholder without regard to the limitations described in footnotes (4), (5), (6), (8), (9) and (10) below, and therefore may not represent the number of shares or percentage of shares the stockholder is deemed to beneficially own under applicable securities laws. On April 27, 2006, each share of Series D Preferred Stock was convertible into approximately 4,255 shares of our Common Stock and each share of Series E Preferred Stock was convertible into approximately

2,000 shares of
our Common
Stock.

- (4) This entity owns shares of our Series D Preferred Stock. Pursuant to the terms of the Certificate of Designation for the Series D Preferred Stock, the number of shares of our common stock that may be acquired by any holder of Series D Preferred Stock upon any conversion of the preferred stock or that shall be entitled to voting rights is limited to the extent necessary to ensure that, following such conversion, the number of shares of our common stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of common stock would be aggregated with the holder's for purposes of the Securities and Exchange Act of 1934, as

amended, does not exceed 4.95% of the total number of shares of our common stock then outstanding.

- (5) This entity owns shares of our Series E Preferred Stock. Pursuant to the terms of the Certificate of Designation of the Series E Preferred Stock, the number of shares of our common stock that may be acquired by any holder of our Series E Preferred Stock upon any conversion of the Series E Preferred Stock or that shall be entitled to voting rights is limited to the extent necessary to ensure that, following such conversion, the number of shares of our common stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of common stock would be

aggregated with the holder s for purposes of the Exchange Act, does not exceed 4.95% of the total number of shares of our common stock then outstanding.

- (6) This entity owns warrants which provide that the number of shares of our Common Stock that may be acquired by any holder of the warrants upon exercise of the warrants is limited to the extent necessary to ensure that, following such exercise, the number of shares of our Common Stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the holder s for purposes of the Exchange Act, does not exceed 9.99% of the total number of shares of our Common Stock then

outstanding.

- (7) Based on information provided to us by the holder, Dorset Management Corporation provides investment management services to certain entities that own shares of common stock and warrants totaling 1,098,300 shares of common stock and 500,000 warrants. David M. Knott is the natural person who exercises voting and investment control over the securities beneficially owned by Dorset Management Corporation. Knott Partners, LP owns 340,400 shares and 179,500 warrants, Matterhorn Offshore Fund Ltd owns 480,200 shares and 196,700 warrants, CommonFund Hedged Equity Co. owns 41,000 shares

and 22,550 warrants, Good Steward Trading Co. owns 12,800 shares and 6,400 warrants, Shoshone Partners, LP owns 210,100 shares and 89,250 warrants, Finderne LLC owns 13,800 shares and 5,600 warrants.

- (8) The entity owns warrants which provide that the number of shares of our Common Stock that may be acquired by any holder of the warrants upon exercise of the warrants is limited to the extent necessary to ensure that, following such exercise, the number of shares of our Common Stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the holder's for purposes of the Exchange Act, does not exceed

4.95% of the total number of shares of our Common Stock then outstanding.

- (9) This entity owns warrants which provide that the number of shares of our Common Stock that may be acquired by any holder of the warrants upon exercise of the warrants is limited to the extent necessary to ensure that, following such exercise, the number of shares of our Common Stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the holder's for purposes of the Exchange Act, does not exceed 9.95% of the total number of shares of our Common Stock then outstanding.

- (10) This entity owns warrants which provide that the

number of shares of our Common Stock that may be acquired by any holder of the warrants upon exercise of the warrants is limited to the extent necessary to ensure that, following such exercise, the number of shares of our Common Stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the holder's for purposes of the Exchange Act, does not exceed 4.99% of the total number of shares of our Common Stock then outstanding.

- (11) Based on information provided to us by the holder, North Sound Capital LLC (North Sound) may be deemed the beneficial owner of the securities described herein in its capacity as

the managing member of North Sound Legacy Institutional Fund LLC and the investment advisor of North Sound Legacy International Ltd. (the Funds), who are the holders of such securities. As the managing member or investment advisor, respectively, of the Funds, North Sound has voting and investment control with respect to the securities held by the Funds. The ultimate managing member of North Sound is Thomas McAuley. North Sound s beneficial ownership as presented above includes 1,991,186 shares of Common Stock issuable upon exercise of warrants; the effect of converting the 78 shares of Series D Preferred Stock into 331,915

shares of
Common Stock;
and the effect of
converting the
120 shares of
Series E
Preferred Stock
into 240,000
shares of
Common Stock,
although North
Sound may not
be deemed to
beneficially own
certain of such
securities under
applicable
securities laws.

- (12) Based on
information
provided to us
by the holder,
Omicron
Capital, L.P. is a
related entity to
Omicron Master
Trust, and
therefore, their
holdings have
been aggregated
for purposes of
this table.
Omicron s
beneficial
ownership
includes
206,314 shares
of Common
Stock issuable
upon exercise of
warrants and the
effect of
converting the
150 shares of
Series E
Preferred Stock
into 300,000
shares of
Common Stock.
Omicron

Capital, L.P., a Delaware limited partnership (Omicron Capital), serves as investment manager to Omicron Master Trust, a trust formed under the laws of Bermuda (Omicron), Omicron Capital, Inc., a Delaware corporation (OCI), serves as general partner of Omicron Capital, and Winchester Global Trust Company Limited (Winchester) serves as the trustee of Omicron. By reason of such relationships, Omicron Capital and OCI may be deemed to share dispositive power over the shares of our Common Stock owned by Omicron, and Winchester may be deemed to share voting and dispositive power over the shares of our Common Stock owned by Omicron.

Capital, OCI
and Winchester
disclaim
beneficial
ownership of
such shares of
our Common
Stock. Omicron
Capital has
delegated
authority from
the board of
directors of
Winchester
regarding the
portfolio
management
decisions with
respect to the
shares of
Common Stock
owned by
Omicron and, as
of April 27,
2006,
Mr. Olivier H.
Morali and
Mr. Bruce T.
Bernstein,
officers of OCI,
have delegated
authority from
the board of
directors of OCI
regarding the
portfolio
management
decisions of
Omicron Capital
with respect to
the shares

Table of Contents

of Common Stock owned by Omicron. By reason of such delegated authority, Messrs. Morali and Bernstein may be deemed to share dispositive power over the shares of our Common Stock owned by Omicron. Messrs. Morali and Bernstein disclaim beneficial ownership of such shares of our Common Stock and neither of such persons has any legal right to maintain such delegated authority. No other person has sole or shared voting or dispositive power with respect to the shares of our Common Stock owned by Omicron, as those terms are used for purposes under Regulation 13D-G of the Exchange Act, as amended. Omicron and Winchester are not affiliates of one another, as that term is used for purposes of the Securities Exchange Act of 1934, as amended, or of any other person named in this 10-K/A, Amendment No. 1

as a stockholder.

No person or group (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended, or the SEC's Regulation 13D-G) controls Omicron and Winchester.

- (13) Based on information provided to us by the holder, OrbiMed Advisors LLC and OrbiMed Capital LLC are registered investment advisers under the Investment Advisers Act of 1940, as amended, that act as investment advisers or general partners to certain clients which hold shares of our Common Stock, as more particularly described above. OrbiMed Advisors LLC and OrbiMed Capital LLC are related entities under common ownership and control. Samuel D. Isaly is the managing member of OrbiMed Advisors LLC and OrbiMed Capital LLC and as such maintains voting control of the shares in the Company. OrbiMed

Advisors LLC and OrbiMed Capital LLC hold shares on behalf of Caduceus Capital Master Fund Limited (589,062 shares and 294,531 warrants), Caduceus Capital II, L.P. (306,000 shares and 153,000 warrants), UBS Eucalyptus Fund, LLC (500,000 shares and 250,000 warrants), PW Eucalyptus Fund, Ltd. (50,000 shares and 25,000 warrants), HFR SHC Aggressive Trust (117,000 shares and 58,500 warrants), Knightsbridge Post Venture IV L.P. (71,000 shares and 35,500 warrants), Knightsbridge Integrated Holdings, V, LP (79,000 shares and 39,500 warrants), Knightsbridge Netherlands II, LP (20,000 shares and 10,000 warrants), Knightsbridge Integrated Holdings IV Post Venture, LP (30,000 shares and 15,000 warrants), Knightsbridge Post Venture III, LP (19,500 shares and 9,750 warrants), Knightsbridge Netherlands I LP (18,800 shares and 9,400 warrants),

Knightsbridge
Netherlands III LP
(19,300 shares and
9,650 warrants),
Knightsbridge
Integrated Holdings
II Limited (24,500
shares and 12,250
warrants),
Knightsbridge
Venture
Completion 2005
LP (7,500 shares
and 3,750
warrants), and
Knightsbridge
Venture Capital VI
LP (20,300 shares
and 10,150
warrants),
Knightsbridge
Venture Capital IV
LP (19,200 shares
and 9,600
warrants), and
Knightsbridge
Venture Capital III
LP (13,600 shares
and 6,800
warrants).

- (14) Based on
information
provided to us by
the holder, SDS
Capital Group SPC,
Ltd. s beneficial
ownership includes
1,304,256 shares of
Common Stock
issuable upon
exercise of warrants
and the effect of
converting the 49
shares of Series D
Preferred Stock into
207,957 shares of
Common Stock.
SDS Management,
LLC is the
Investment

Manager of SDS Capital Group SPC, Ltd. Steve Derby is the sole Managing Member of SDS Management, LLC, and is the natural person who exercises voting and investment control over the securities beneficially owned by SDS Capital Group SPC, Ltd.

The following table sets forth information, about our shares of Common Stock that are or may be beneficially owned on April 27, 2006 (unless otherwise indicated) by (i) each Named Executive Officer (as defined on page 21); (ii) each of our directors and director nominees; and (iii) our directors and executive officers as a group. Unless otherwise noted, each stockholder has sole voting power and sole investment power with respect to the securities shown in the table below.

| Name of Beneficial Owner | Shares Owned(1) | Percent of Shares Outstanding |
|---|------------------------|--------------------------------------|
| Named Executive Officers | | |
| Shrotriya, Rajesh(2) | 1,378,562 | 5.4% |
| Lenaz, Luigi(3) | 509,684 | 2.1% |
| Shyam Kumaria(4) | 153,486 | * |
| Directors/Director Nominees | | |
| Fulmer, Richard (5) | 18,750 | * |
| Krassner, Stuart(5) | 19,500 | * |
| Maida, Anthony(5) | 43,750 | * |
| Mehta, Dilip(5) | 50,750 | * |
| Vida, Julius(5) | 50,750 | * |
| All Executive Officers and Directors as a group (8 persons)(6) | 2,225,232 | 8.5% |

* less than 1%

(1) Shares of Common Stock owned as of April 27, 2006 and shares of Common Stock subject to options and warrants currently exercisable or exercisable

within 60 days
of April 27,
2006, are
deemed
beneficially
owned and
outstanding for
computing the
percentage of
the person
holding such
securities, but
are not
considered
outstanding for
computing the
percentage of
any other
person.

Table of Contents

- (2) Includes 1,255,100 shares of our Common Stock subject to stock options held by Dr. Shrotriya, which are currently exercisable or exercisable within 60 days of April 27, 2006. The number does not include 200 shares of our Common Stock beneficially owned by Rick Shrotriya, Dr. Rajesh C. Shrotriya's adult son, for which Dr. Shrotriya disclaims beneficial ownership.
- (3) Includes 404,150 shares of our Common Stock subject to stock options held by Dr. Luigi Lenaz, and 30,000 shares of our Common Stock subject to a currently exercisable option held by his wife, M. Dianne DeFuria, which are currently exercisable or exercisable

within 60 days
of April 27,
2006.

(4) Includes
127,500 shares
of our Common
Stock subject to
stock options
held by
Mr. Kumaria,
which are
currently
exercisable or
exercisable
within 60 days
of April 27,
2006.

(5) Represents
shares of our
Common Stock
subject to stock
options which
are currently
exercisable or
exercisable
within 60 days
of April 27,
2006.

(6) Includes
1,974,500
shares of our
Common Stock
subject to stock
options which
are current
exercisable or
exercisable
within 60 days
of April 27,
2006.

Item 13. *Certain Relationships and Related Transactions*

On September 15, 2005, we completed the sale in a registered transaction to select institutional and other investors of 8,000,000 shares of our Common Stock at a purchase price of \$5.25 per share, and six-year warrants, which are immediately exercisable, to purchase up to 4,000,000 shares of our Common Stock at an exercise price of \$6.62 per share, for aggregate proceeds of approximately \$42 million. Pursuant to the purchase agreements with the investors, we have filed a registration statement covering the Common Stock and the Common Stock issuable upon exercise of the warrants.

Among the investors in this financing were the following entities that are current beneficial owners of more than 5% of the total number of outstanding shares of our Preferred Stock or Common Stock. Entities related to OrbiMed Advisors, LLC acquired 1,904,762 shares of our Common Stock and warrants to purchase up to 952,381 shares of our Common Stock for an aggregate purchase price of \$10,000,000. Entities related to David M. Knott acquired 1,000,000 shares of our Common Stock and warrants to purchase up to 500,000 shares of our Common Stock for an aggregate purchase price of \$5,250,000. SDS Capital Group, SPC, Ltd. acquired 550,000 shares of our Common Stock and warrants to purchase up to 275,000 shares of our Common Stock for an aggregate purchase price of \$2,887,500.

Please see the table above under the Section titled "Stock Ownership" for more information on the above entities and their current holdings.

In 2001, prior to his election to the Board of Directors in April 2003, Dr. Vida had participated as a consultant in the in-licensing of satraplatin from Johnson Matthey. Pursuant to his Consulting Agreement, which terminated in September 2001, Dr. Vida was paid an aggregate of \$7,500 in success fees. He may become eligible for additional success fees equal to 3% of amounts paid by us under the license agreement, other than royalties, in the event the contingent milestone obligations to Johnson Matthey become payable. Such fees are unrelated to his services as a director.

Item 14. Principal Accountant Fees and Services

Audit and Non-Audit Fees

The following summarizes audit and non-audit fees for the years ended December 31, 2005 and 2004.

| | 2005 | 2004 |
|--------------------|-------------|-------------|
| Audit Fees | \$ 222,366 | \$ 239,533 |
| Audit Related Fees | 28,309 | 28,955 |
| Tax Fees | 8,015 | 6,400 |
| All Other Fees | 0 | 0 |
| Total | \$ 258,690 | \$ 274,888 |

Table of Contents

Kelly & Company. The fees billed (including estimations for services rendered but not yet billed) by Kelly & Company, our current independent public accountant, during or related to 2005 and 2004 were as follows:

Audit Fees. The aggregate fees billed for professional services rendered by Kelly & Company for the audit of the Company's annual financial statements and the review of the financial statements included in the Company's Quarterly Reports on Forms 10-Q for the year ended December 31, 2005 were \$222,366, and for the year ended December 31, 2004 were \$239,533.

Audit Related Fees. The aggregate fees billed for professional services rendered by Kelly & Company for assurance and related services that are reasonably related to the performance of the audit for the 2005 fiscal year were \$28,309, and for the 2004 fiscal year were \$28,955. Such fees primarily related to reviews of registration statements filed in connection with equity financings secured in 2005 and 2004.

Tax Fees. The aggregate fees billed for professional services rendered by Kelly & Company for tax returns and compliance for 2005 was \$8,015, and was approximately \$6,400 for 2004.

All Other Fees. The aggregate fees billed for services rendered by Kelly & Company, other than fees for the services referenced under the foregoing captions for both the 2005 and 2004 fiscal years were \$0.

All audit and permissible non-audit services by our independent accountant were pre-approved by our Audit Committee. Pursuant to its charter, the Audit Committee may establish pre-approval policies and procedures, subject to SEC and NASDAQ rules and regulations, to approve audit and permissible non-audit services, however, it has not yet done so.

PART IV

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K

(a)(3) Exhibits.

Exhibit

| No. | Description |
|------------|--|
| 2.1 + # | Asset Purchase Agreement by and between the Registrant, Targent Inc. and Certain Stockholders of Targent, Inc., dated March 17 2006. |
| 10.1 + # | Development and Marketing Agreement between the Registrant and Par Pharmaceutical, Inc. dated February 22, 2006. |
| 10.2 + | Voting Agreement by and Among the Registrant and Certain Stockholders of Targent, Inc. dated March 17, 2006. |
| 10.3 +* | Summary of Director Compensation. |
| 31.1 + | Certification of Chief Executive Officer, pursuant to Rule 13a-14 promulgated under the Exchange Act, as created by Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 + | Certification of Vice President Finance, pursuant to Rule 13a-14 promulgated under the Exchange Act, as created by Section 302 of the Sarbanes-Oxley Act of 2002. |

* Indicates a management contract or compensatory plan or

arrangement.

+ Filed herewith

Confidential portions omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2

promulgated under the Securities Exchange Act of 1934, as amended.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.

SPECTRUM PHARMACEUTICALS,
INC.

By: /s/ RAJESH C. SHROTRIYA,
M.D.

Rajesh C. Shrotriya, M.D.
*Chief Executive Officer and
President*

Date: May 1, 2006

Table of Contents

EXHIBIT INDEX

Exhibit

| No. | Description |
|------------|--|
| 2.1 +# | Asset Purchase Agreement by and between the Registrant, Targent Inc. and Certain Stockholders of Targent, Inc., dated March 17 2006. |
| 10.1 +# | Development and Marketing Agreement between the Registrant and Par Pharmaceutical, Inc. dated February 22, 2006. |
| 10.2 + | Voting Agreement by and Among the Registrant and Certain Stockholders of Targent, Inc. dated March 17, 2006. |
| 10.3 +* | Summary of Director Compensation. |
| 31.1+ | Certification of Chief Executive Officer, pursuant to Rule 13a-14 promulgated under the Exchange Act, as created by Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2+ | Certification of Vice President Finance, pursuant to Rule 13a-14 promulgated under the Exchange Act, as created by Section 302 of the Sarbanes-Oxley Act of 2002. |

* Indicates a management contract or compensatory plan or arrangement.

+ Filed herewith.

Confidential portions omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.